Short Term Trading Member Forum

[noretreat]

AVXL - RMZPORT- That slide in post 32618 could hardly be any better. I think if the numbers were any better I'd be suspicious of the data. On several key measures and in just 5 weeks AD patients moved dramatically from baseline toward the cognitive measures of healthy people. As far as I know no other treatment has ever shown this.

There are at least three issues that could be picked on by naysayers, however. First, of course, is sample size. 32 patients is great for a p2 but no conclusions can be drawn from this. This just becomes the basis for p3 and a much larger sample. Second, there is the questions of whether this is transitory. I want to see much more data over a longer period. Third is whether this is a placebo effect. I'm quite sure we will see a control group in a blinded p3. All of these questions can be raised about ANY open-label p2 and are some of the key reasons that a p3 is required.

The above should make for a lively discussion Monday. Is $8 the right price for AVXL at this point? Well....I'm not making any predictions. $8 is up quite a bit over the last few months and clearly the stock has been overheated. The long-term outlook for AVXL is quite good...that is without question.